Switch theme
Sign up to access all valuation multiples
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
2015
294
LTM Revenue $73.3M
LTM EBITDA -$50.3M
$525M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Beta Bionics has a last 12-month revenue (LTM) of $73.3M and a last 12-month EBITDA of -$50.3M.
In the most recent fiscal year, Beta Bionics achieved revenue of $65.1M and an EBITDA of -$43.0M.
Beta Bionics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Beta Bionics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $73.3M | XXX | $65.1M | XXX | XXX | XXX |
| Gross Profit | $39.2M | XXX | $35.9M | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | -$50.3M | XXX | -$43.0M | XXX | XXX | XXX |
| EBITDA Margin | -69% | XXX | -66% | XXX | XXX | XXX |
| EBIT | -$58.4M | XXX | -$45.3M | XXX | XXX | XXX |
| EBIT Margin | -80% | XXX | -69% | XXX | XXX | XXX |
| Net Profit | -$66.6M | XXX | -$54.8M | XXX | XXX | XXX |
| Net Margin | -91% | XXX | -84% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Beta Bionics's stock price is $17.
Beta Bionics has current market cap of $749M, and EV of $525M.
See Beta Bionics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $525M | $749M | XXX | XXX | XXX | XXX | $-5.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Beta Bionics has market cap of $749M and EV of $525M.
Beta Bionics's trades at 8.1x EV/Revenue multiple, and -12.2x EV/EBITDA.
Equity research analysts estimate Beta Bionics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Beta Bionics has a P/E ratio of -11.3x.
See valuation multiples for Beta Bionics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $749M | XXX | $749M | XXX | XXX | XXX |
| EV (current) | $525M | XXX | $525M | XXX | XXX | XXX |
| EV/Revenue | 7.2x | XXX | 8.1x | XXX | XXX | XXX |
| EV/EBITDA | -10.4x | XXX | -12.2x | XXX | XXX | XXX |
| EV/EBIT | -9.0x | XXX | -11.6x | XXX | XXX | XXX |
| EV/Gross Profit | 13.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.3x | XXX | -13.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBeta Bionics's last 12 month revenue growth is 33%
Beta Bionics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Beta Bionics's rule of 40 is -316% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Beta Bionics's rule of X is 14% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Beta Bionics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Margin | -69% | XXX | -66% | XXX | XXX | XXX |
| EBITDA Growth | 35% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -316% | XXX | -33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 125% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Beta Bionics acquired XXX companies to date.
Last acquisition by Beta Bionics was XXXXXXXX, XXXXX XXXXX XXXXXX . Beta Bionics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Beta Bionics founded? | Beta Bionics was founded in 2015. |
| Where is Beta Bionics headquartered? | Beta Bionics is headquartered in United States of America. |
| How many employees does Beta Bionics have? | As of today, Beta Bionics has 294 employees. |
| Who is the CEO of Beta Bionics? | Beta Bionics's CEO is Mr. Sean Saint. |
| Is Beta Bionics publicy listed? | Yes, Beta Bionics is a public company listed on NAS. |
| What is the stock symbol of Beta Bionics? | Beta Bionics trades under BBNX ticker. |
| When did Beta Bionics go public? | Beta Bionics went public in 2025. |
| Who are competitors of Beta Bionics? | Similar companies to Beta Bionics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Beta Bionics? | Beta Bionics's current market cap is $749M |
| What is the current revenue of Beta Bionics? | Beta Bionics's last 12 months revenue is $73.3M. |
| What is the current revenue growth of Beta Bionics? | Beta Bionics revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of Beta Bionics? | Current revenue multiple of Beta Bionics is 7.2x. |
| Is Beta Bionics profitable? | Yes, Beta Bionics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Beta Bionics? | Beta Bionics's last 12 months EBITDA is -$50.3M. |
| What is Beta Bionics's EBITDA margin? | Beta Bionics's last 12 months EBITDA margin is -69%. |
| What is the current EV/EBITDA multiple of Beta Bionics? | Current EBITDA multiple of Beta Bionics is -10.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
